Lamellar Biomedical Secures its First Orphan Drug Licence
20-Jun-2011 -
Lamellar Biomedical Ltd announced that their lead clinical candidate LMS-611 for the treatment of patients with cystic fibrosis has received Orphan Drug Designation from the European Commission. The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) ...
cystic fibrosis
Lamellar Biomedical
Orphan Drug Designation
+2